Johnson & Johnson Pharmaceutical Research & Development, L.L.C. in Raritan says it has received an approvable letter from the Food and Drug Administration (FDA) for Risperdal (risperidone) to treat ...

UZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY reduced the risk of relapse by up ...

PARSIPPANY, N.J. & TEL AVIV, Israel & PARIS--(BUSINESS WIRE)-- Regulatory News: Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Medincell ...

Teva announces positive real-world outcomes for UZEDY® and TEV-'749 in schizophrenia treatment, highlighting improved adherence and reduced hospital visits. Teva Pharmaceuticals has announced positive ...

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the publication of efficacy ...

Amneal has received the Food and Drug Administration’s approval of risperidone extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, which is the generic of ...

March 24, 2010 — One year of maintenance risperidone administered at the initial therapeutic dose for acute schizophrenia is more effective at preventing relapse than dose reduction strategies and is ...

NEW YORK, June 21 (Reuters) - Johnson & Johnson on Thursday said U.S. regulators have given conditional approval for use of its drug Risperdal as a treatment for adolescents with schizophrenia and ...

Patients. A total of 675 patients were involved in the ITT analysis (risperidone group, n = 349; conventional antipsychotic group, n = 326). The baseline demographics and the clinical characteristics ...

In 1993, Johnson & Johnson owned schizophrenia. That multimillion segment of the antipsychotic market had long been an untapped income source, populated by old-school generics that came with their ...